<DOC>
	<DOCNO>NCT00831181</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) surgery may kill tumor cell may make tumor small reduce amount normal tissue need remove . Giving oxaliplatin , leucovorin , fluorouracil surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study side effect well give combination chemotherapy work treat patient undergo surgery rectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients Undergoing Surgery Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess complete pathologic response rate patient rectal cancer treat modify neoadjuvant FOLFOX 6 chemotherapy follow total mesorectal excision adjuvant modify FOLFOX 6 chemotherapy . Secondary - To observe overall pathologic response rate patient . - To correlate pathologic stag preoperative ultrasound pelvic MRI staging . - To assess toxic side effect regimens patient . - To assess pattern disease relapse , disease-free survival outcome , overall survival outcomes patient . OUTLINE : - Neoadjuvant therapy : Patients receive modify FOLFOX 6 chemotherapy comprise oxaliplatin leucovorin calcium IV 2 hour day 1 continuous fluorouracil IV 46 hour day 1-2 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients proceed surgery . - Surgery : Patients undergo total mesorectal excision anterior resection abdominal perineal resection within 4 week completion neoadjuvant therapy . - Adjuvant therapy : Within 4 week surgery , patient receive modify FOLFOX 6 chemotherapy comprise oxaliplatin leucovorin calcium IV 2 hour day 1 continuous fluorouracil IV 46 hour day 1-2 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients complete quality life assessment questionnaires baseline follow-up visit . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum T3 , N0 , M0 T13 , N1 , M0 disease assess clinical exam , transrectal ultrasound , MRI , CT scan No preoperative evidence T4 , N2 distal lesion ( 06 cm anal verge ) Distal border tumor must ≥ 6 cm anal verge preoperative proctoscopy patient leave lateral decubitus position Proximal border tumor must ≤ 12 cm anal verge proctoscopic examination No known distant metastases No positive circumferential margin PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 60100 % ECOG PS 01 ANC ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN ALT ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No serious comorbid disease , include psychiatric disorder cardiopulmonary disease precludes full delivery study treatment No cancer diagnosis within past 5 year , except nonmelanomatous skin cancer situ carcinoma cervix No history clinically significant peripheral neuropathy current symptom neuropathy , define ≥ grade 2 neurosensory neuromotor toxicity No history allergic reaction attribute compound similar chemical biological composition fluorouracil , oxaliplatin , leucovorin calcium No HIV positivity PRIOR CONCURRENT THERAPY : No prior chemotherapy pelvic irradiation No concurrent investigational agent No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent halogenated antiviral agent ( e.g. , sorivudine brivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>